SK285962B6 - Použitie činidla rušiaceho väzbu CD40:CD154 na zmiernenie závažnosti syndrómu inhibície exogénneho proteínu - Google Patents

Použitie činidla rušiaceho väzbu CD40:CD154 na zmiernenie závažnosti syndrómu inhibície exogénneho proteínu Download PDF

Info

Publication number
SK285962B6
SK285962B6 SK1803-99A SK180399A SK285962B6 SK 285962 B6 SK285962 B6 SK 285962B6 SK 180399 A SK180399 A SK 180399A SK 285962 B6 SK285962 B6 SK 285962B6
Authority
SK
Slovakia
Prior art keywords
antibodies
fviii
binding
protein
antibody
Prior art date
Application number
SK1803-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK180399A3 (en
Inventor
Burt Adelman
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of SK180399A3 publication Critical patent/SK180399A3/sk
Publication of SK285962B6 publication Critical patent/SK285962B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1803-99A 1997-06-20 1998-06-19 Použitie činidla rušiaceho väzbu CD40:CD154 na zmiernenie závažnosti syndrómu inhibície exogénneho proteínu SK285962B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
SK180399A3 SK180399A3 (en) 2000-06-12
SK285962B6 true SK285962B6 (sk) 2007-12-06

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1803-99A SK285962B6 (sk) 1997-06-20 1998-06-19 Použitie činidla rušiaceho väzbu CD40:CD154 na zmiernenie závažnosti syndrómu inhibície exogénneho proteínu

Country Status (25)

Country Link
US (1) US20020119151A1 (de)
EP (1) EP1034001B1 (de)
JP (1) JP2002504910A (de)
KR (1) KR100567998B1 (de)
CN (2) CN1261285A (de)
AT (1) ATE272408T1 (de)
AU (1) AU733062B2 (de)
BG (1) BG64436B1 (de)
BR (1) BR9810755A (de)
CA (1) CA2294138A1 (de)
CZ (1) CZ295805B6 (de)
DE (1) DE69825473T2 (de)
EA (1) EA002512B1 (de)
EE (1) EE9900587A (de)
ES (1) ES2226152T3 (de)
HK (1) HK1031825A1 (de)
HU (1) HUP0002048A3 (de)
IL (1) IL133305A0 (de)
IS (1) IS2097B (de)
NO (1) NO996274L (de)
NZ (1) NZ502051A (de)
PT (1) PT1034001E (de)
SK (1) SK285962B6 (de)
TR (1) TR199903141T2 (de)
WO (1) WO1998058672A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL346796A1 (en) * 1998-09-21 2002-02-25 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
IES20030305A2 (en) * 2002-04-23 2003-10-29 Desmond Joseph Fitzgerald Inhibition of platelet aggregation
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
ZA200604419B (en) 2003-11-04 2008-06-25 Novartis Vaccines & Diagnostic Antagonist anti-CD40 monoclonal antibodies and methods for their use
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
PT1034001E (pt) 2004-12-31
EP1034001A1 (de) 2000-09-13
NO996274L (no) 2000-02-18
SK180399A3 (en) 2000-06-12
NZ502051A (en) 2001-04-27
EP1034001B1 (de) 2004-08-04
CZ458899A3 (cs) 2000-04-12
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
IS2097B (is) 2006-04-12
JP2002504910A (ja) 2002-02-12
ATE272408T1 (de) 2004-08-15
NO996274D0 (no) 1999-12-17
WO1998058672A1 (en) 1998-12-30
BR9810755A (pt) 2000-08-15
US20020119151A1 (en) 2002-08-29
CN1261285A (zh) 2000-07-26
DE69825473T2 (de) 2005-08-04
EA200000059A1 (ru) 2000-08-28
EA002512B1 (ru) 2002-06-27
KR20010013964A (ko) 2001-02-26
BG64436B1 (en) 2005-02-28
TR199903141T2 (xx) 2000-09-21
IL133305A0 (en) 2001-04-30
ES2226152T3 (es) 2005-03-16
HUP0002048A2 (hu) 2000-10-28
IS5274A (is) 1999-11-26
CN1651071A (zh) 2005-08-10
BG104092A (en) 2000-10-31
AU8153698A (en) 1999-01-04
HK1031825A1 (en) 2001-06-29
CA2294138A1 (en) 1998-12-30
KR100567998B1 (ko) 2006-04-07
DE69825473D1 (de) 2004-09-09
CZ295805B6 (cs) 2005-11-16
AU733062B2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
JP7110023B2 (ja) 腫瘍療法のためのｉｌ－１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
JP3616091B2 (ja) 自己免疫疾患および炎症性疾患の治療
Foy et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.
AU735592B2 (en) Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
EP1034001B1 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
SK288287B6 (sk) Protilátka proti sekvencii SEQ ID No: 1 alebo polypeptid s jej obsahom a ich použitie
KR101800467B1 (ko) 루푸스 치료 방법 및 조성물
CN114007700A (zh) 抗FcRn抗体在治疗天疱疮和类天疱疮疾病中的用途
US20030161827A1 (en) Therapies that improve graft survival
CA2744670C (en) A b cell depleting agent for the treatment of atherosclerosis
MXPA99011741A (en) Cd154 blockade therapy for therapeutic protein inhibitor syndrome
PL190316B1 (pl) Zastosowanie przerywacza wiązania CD40:CD154
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
CA2483630A1 (en) Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations